In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

J&J will acquire Tibotec-Virco NV

Executive Summary

Johnson & Johnson has agreed to acquire all the assets of Tibotec-Virco NV, a closely held biotech with diagnostics and clinical-phase drugs in HIV and other viral diseases. J&J will pay about $320mm in cash and assumed debt.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Cash

Related Companies

Advertisement
UsernamePublicRestriction

Register